Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Impact of new criteria for anticoagulant treatment in atrial fibrillation.

Rodríguez-Mañero M, Cordero A, Bertomeu-González V, Moreno-Arribas J, Bertomeu-Martínez V, Mazón P, Fácila L, Cosín J, Lekuona I, Galve E, González-Juanatey JR.

Rev Esp Cardiol. 2011 Aug;64(8):649-53. doi: 10.1016/j.recesp.2011.03.014. Epub 2011 Jun 8. English, Spanish.

2.
3.

Can we predict stroke in atrial fibrillation?

Lip GY.

Clin Cardiol. 2012 Jan;35 Suppl 1:21-7. doi: 10.1002/clc.20969. Review.

4.

Very low risk of thromboembolic events in patients undergoing successful catheter ablation of atrial fibrillation with a CHADS2 score ≤3: a long-term outcome study.

Saad EB, d'Avila A, Costa IP, Aryana A, Slater C, Costa RE, Inácio LA Jr, Maldonado P, Neto DM, Camiletti A, Camanho LE, Polanczyk CA.

Circ Arrhythm Electrophysiol. 2011 Oct;4(5):615-21. doi: 10.1161/CIRCEP.111.963231. Epub 2011 Aug 13.

5.

Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.

Friberg L, Rosenqvist M, Lip GY.

Eur Heart J. 2012 Jun;33(12):1500-10. doi: 10.1093/eurheartj/ehr488. Epub 2012 Jan 13.

6.

Reliable identification of "truly low" thromboembolic risk in patients initially diagnosed with "lone" atrial fibrillation: the Belgrade atrial fibrillation study.

Potpara TS, Polovina MM, Licina MM, Marinkovic JM, Prostran MS, Lip GY.

Circ Arrhythm Electrophysiol. 2012 Apr;5(2):319-26. doi: 10.1161/CIRCEP.111.966713. Epub 2012 Feb 8.

7.

Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation.

Mason PK, Lake DE, DiMarco JP, Ferguson JD, Mangrum JM, Bilchick K, Moorman LP, Moorman JR.

Am J Med. 2012 Jun;125(6):603.e1-6. doi: 10.1016/j.amjmed.2011.09.030. Epub 2012 Apr 11.

8.

Improving thromboprophylaxis using atrial fibrillation diagnostic capabilities in implantable cardioverter-defibrillators: the multicentre Italian ANGELS of AF Project.

Boriani G, Santini M, Lunati M, Gasparini M, Proclemer A, Landolina M, Padeletti L, Botto GL, Capucci A, Bianchi S, Biffi M, Ricci RP, Vimercati M, Grammatico A, Lip GY; Italian ClinicalService Project.

Circ Cardiovasc Qual Outcomes. 2012 Mar 1;5(2):182-8. doi: 10.1161/CIRCOUTCOMES.111.964205. Epub 2012 Feb 28.

9.

Additive effect of the metabolic syndrome score to the conventional CHADS₂ score for the thromboembolic risk stratification of patients with atrial fibrillation.

Tsai CT, Chang SH, Chang SN, Hwang JJ, Wu CK, Wang YC, Tseng CD, Yeh HM, Lai LP, Chiang FT, Lin JL.

Heart Rhythm. 2014 Mar;11(3):352-7. doi: 10.1016/j.hrthm.2013.11.014. Epub 2013 Nov 16.

PMID:
24252289
10.

Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients.

Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA.

Europace. 2014 Feb;16(2):195-201. doi: 10.1093/europace/eut244. Epub 2013 Sep 12.

11.

Comparison between CHADS2 and CHA2 DS2 -VASc score in a stroke cohort with atrial fibrillation.

Giralt-Steinhauer E, Cuadrado-Godia E, Ois A, Jiménez-Conde J, Rodríguez-Campello Á, Soriano C, Roquer J.

Eur J Neurol. 2013 Apr;20(4):623-8. doi: 10.1111/j.1468-1331.2012.03807.x. Epub 2012 Jul 27.

PMID:
22834861
12.

Oral anticoagulation in nonvalvular atrial fibrillation in clinical practice: impact of CHADS(2) score on outcome.

Ruiz Ortiz M, Romo E, Mesa D, Delgado M, Anguita M, Castillo JC, Arizón JM, Suárez de Lezo J.

Cardiology. 2010;115(3):200-4. doi: 10.1159/000284450. Epub 2010 Feb 17.

PMID:
20160440
13.

CHADS(2) and CHA(2)DS (2)-VASc score of patients with atrial fibrillation or flutter and newly detected left atrial thrombus.

Wasmer K, Köbe J, Dechering D, Milberg P, Pott C, Vogler J, Stypmann J, Waltenberger J, Mönnig G, Breithardt G, Eckardt L.

Clin Res Cardiol. 2013 Feb;102(2):139-44. doi: 10.1007/s00392-012-0507-4. Epub 2012 Sep 15.

PMID:
22983022
14.

The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy.

Coppens M, Eikelboom JW, Hart RG, Yusuf S, Lip GY, Dorian P, Shestakovska O, Connolly SJ.

Eur Heart J. 2013 Jan;34(3):170-6. doi: 10.1093/eurheartj/ehs314. Epub 2012 Sep 27.

15.

Thromboembolic risk evaluation in patients with atrial fibrillation using a modified CHADS(2) scoring system.

Cha MJ, Oh GC, Hahn S, Choi EK, Oh S.

J Cardiovasc Electrophysiol. 2012 Feb;23(2):155-62. doi: 10.1111/j.1540-8167.2011.02181.x. Epub 2011 Sep 28.

PMID:
21955174
16.

Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study.

Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C.

BMJ. 2011 Jan 31;342:d124. doi: 10.1136/bmj.d124.

17.

Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).

Healey JS, Hart RG, Pogue J, Pfeffer MA, Hohnloser SH, De Caterina R, Flaker G, Yusuf S, Connolly SJ.

Stroke. 2008 May;39(5):1482-6. doi: 10.1161/STROKEAHA.107.500199. Epub 2008 Mar 6.

18.

Prevalence and antithrombotic management of atrial fibrillation in hospitalised patients.

Berti D, Moors E, Moons P, Heidbuchel H.

Heart. 2015 Jun;101(11):884-93. doi: 10.1136/heartjnl-2014-307059. Epub 2015 Apr 14.

PMID:
25872523
19.

Comparison of the reliability and validity of four contemporary risk stratification schemes to predict thromboembolism in non-anticoagulated patients with atrial fibrillation.

Abu-Assi E, Otero-Raviña F, Allut Vidal G, Coutado Méndez A, Vaamonde Mosquera L, Sánchez Loureiro M, Caneda Villar MC, Fernández Villaverde JM, Maestro Saavedra FJ, González-Juanatey JR; Grupo Barbanza researchers.

Int J Cardiol. 2013 Jun 5;166(1):205-9. doi: 10.1016/j.ijcard.2011.10.096. Epub 2011 Nov 21.

PMID:
22104995
20.

Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study.

Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, Raunsø J, Tolstrup JS, Hansen PR, Gislason GH, Torp-Pedersen C.

Thromb Haemost. 2011 Oct;106(4):739-49. doi: 10.1160/TH11-05-0364. Epub 2011 Jul 20.

PMID:
21789337
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk